Form 4: Semler Scientific CEO Awarded Stock Options

Semler Scientific's CEO, Douglas Murphy-Chutorian, was granted 50,000 stock options on January 6, 2025, which vest over four years.

Summary

• Douglas Murphy-Chutorian, the CEO of Semler Scientific, Inc., was granted 50,000 stock options on January 6, 2025.
• The options have an exercise price of $58.94.
• The options vest over a four-year period, with 1/4th vesting on the first anniversary of the grant date and the remaining 3/4ths vesting monthly over the following three years.
• The options expire on January 6, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The grant of stock options aligns the CEO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the technology and healthcare industries, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation across various industries, particularly in growth-oriented companies like Semler Scientific.
• The vesting schedule of four years is also typical, encouraging long-term performance and retention.
• Companies like Masimo and Insulet also use stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Semler Scientific, CEO, Douglas Murphy-Chutorian, equity